Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
GAITHERSBURG, Md., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Jeffrey Stoddard, M.D., to the position of Vice President, Medical Affairs. Dr. Stoddard’s efforts will be focused on external engagement with thought leaders, vaccine experts, policymakers and key stakeholders. He will also be responsible for evidence generation related to health economics and outcomes research.
Dr. Stoddard joins Novavax with more than 15 years of vaccine research and development experience and leadership roles. He was instrumental in the commercial launch of multiple vaccines and biologics including Synagis®, FluMist®, pandemic flu vaccines, Menveo® and Bexsero®. He was most recently Vice President, Medical Affairs & Medical Professional Services, at Alkermes plc, where he led medical affairs, and health economics and outcomes research. Prior to Alkermes, Dr. Stoddard held positions of increasing responsibility at Novartis Vaccines, Covance and MedImmune. Dr. Stoddard earned his medical degree from the University of Wisconsin Medical School, a Bachelor of Science degree from the University of Wisconsin-Madison, and completed a residency at Johns Hopkins Hospital and a postdoctoral fellowship in the Pew Health Policy program at the University of California, San Francisco.
“Dr. Stoddard is a foundational building block of the Novavax commercial team,” said John Trizzino, Senior Vice President, Commercial Operations. “His medical and healthcare policy experience will be critical as we develop our disease state awareness and vaccine policy strategy and we look forward to his leadership in educating healthcare providers in anticipation of the commercial launch of our respiratory syncytial virus F-protein nanoparticle vaccine candidate.”
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company’s website, novavax.com.
Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Senior Manager, Investor Relations [email protected] 240-268-2000 Russo Partners, LLC David Schull Todd Davenport, Ph.D. [email protected] [email protected] 212-845-4271
